Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Presidio Property Trust extends Johns Hopkins University lease at Baltimore property to end-2031

Presidio Property Trust extends Johns Hopkins University lease at Baltimore property to end-2031

ReutersReuters2026/08/24 12:30
  • Presidio Property Trust completed a five-year lease extension with its largest tenant, Johns Hopkins University, at its Baltimore property.
  • The tenant occupies 31,752 square feet, covering the entire building.
  • New lease term runs through Dec. 31, 2031.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Presidio Property Trust Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202608240830ACCESSWRNAPR_____1210517) on August 24, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Saving in the US, paying globally? Industry research warns: Trump’s push to lower drug prices could instead incentivize pharmaceutical companies to raise prices overseas

A study published in The Lancet indicates that Trump's efforts to lower drug prices in the United States may force pharmaceutical companies to raise prices internationally or exit certain markets, potentially leading to a significant reduction in the approximately $11.6 billion saved annually by Medicare.

智通财经2026/09/14 00:46
Saving in the US, paying globally? Industry research warns: Trump’s push to lower drug prices could instead incentivize pharmaceutical companies to raise prices overseas